Cell based cancer vaccines
DCprime has both the infrastructure and capabilities to bring cancer immunotherapeutics to clinic. Initially exploiting the proprietary DCOne® platform, DCprime is developing cell based vaccines against different types of cancer.
Immuno-oncology beyond T cells
Since successful vaccination requires an immune system capable of mounting an effective response to the vaccine, DCprime continues to invest in research into furthering understanding of the condition of the immune system during or after treatment of cancer.
- DCprime announces first patient dosed in phase 2 ADVANCE-II study with DCP-001 in patients with Acute Myeloid Leukemia 15 November, 2018 Leiden, The Netherlands, 15 November 2018 – DCprime bv, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 study, called ADVANCE-II. Patients with Acute Myeloid Leukemia (AML) in complete remission after induction therapy but with persistence of measurable residual disease (MRD) ... Read more
- Jeroen Rovers MD, PhD joins DCprime as Chief Medical Officer 1 October, 2018 Leiden, The Netherlands, October 01, 2018 – DCprime announces today that Jeroen Rovers MD, PhD joins the company as its Chief Medical Officer with immediate effect. Jeroen trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 15 years he worked in different academic institutes and companies, lastly ... Read more
- Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy 26 July, 2018 Clinical study data of DCP-001 in AML published in leading journal for new concepts and advances in cancer immunology and immunotherapy. Leiden, The Netherlands, 26 July 2018 – DCprime announces that the results of the phase I study with its lead product DCP-001 in AML have been published in Cancer Immunology, Immunotherapy. The phase I study was ... Read more